Tag: Migraine
Galcanezumab Beats Placebo for Episodic Migraine
Treatment with 120- or 240-mg galcanezumab linked to reduction in migraine days versus placebo
FDA Approves Aimovig to Prevent Migraines
Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo
Fremanezumab Linked to Fewer Monthly Migraine Days
For episodic migraine patients, reduction in number of migraine days with monthly dosing, single dose
AAN: Erenumab Shows Promise for Hard-to-Treat Migraine
Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days
Noninvasive Brain Stimulation May Help Prevent Migraines
Single-pulse transcranial magnetic stimulation device is safe and easy to use
Low Risk of Serotonin Syndrome for Triptans + SSRI/SNRI
Researchers question FDA advisory warning on risk of concomitant use
Migraine Linked to Increased Risk of Cardiovascular Disease
Increased risks of myocardial infarction, ischemic and hemorrhagic stroke, VTE, A-fib, and flutter
Pain Self-Efficacy Questionnaire Helps to Evaluate Migraine Pain
Commonly used pain survey better assesses migraine patients' pain-coping ability and function
Fremanezumab, Erenumab Effective in Treatment of Migraine
Fremanezumab effective in chronic migraine; erenumab beneficial for episodic migraine
ASA: Botox Injections Beneficial for Migraine in Children
Statistically significant changes in migraine intensity, frequency, duration from pre- to post-therapy
